PHXM — Phaxiam Therapeutics SA Share News
0.000.00%
Last trade - 00:00- €0.61m
- €12.08m
- €1.33m
Brief: Erytech Announces Approval To Transfer Its Listing To The Nasdaq Capital Market
Brief: Erytech And Pherecydes Announce Proposed Combination Intending To Create Global Leader In Extended Phage Therapies
Brief: ERYTECH Provides Business And Financial Update For Third Quarter
Brief: Erytech Announces Receipt Of Nasdaq Notice
Brief: Erytech Provides Business And Financial Update For The First Half Of 2022
Brief: Erytech Provides Regulatory Update
Brief: ERYTECH Pharma Reports Q1 Net Loss Of EUR 11.9 Million
U.S. site sale prolongs Erytech's financing, shares extend gains
Erytech to sell U.S. manufacturing facility to Catalent, shares soar
Brief: Erytech Sells U.S. Manufacturing Facility For USD 44.5 Million
Erytech Pharma jumps on cancer study data publication
Brief: ERYTECH Announces Publication Of Positive Results From Eryaspase Phase 2 Trial In Hypersensitive ALL In The British Journal Of Haematology
Brief: Erytech Pharma End-FY Cash and Cash Equivalents Down At EUR 33.7 Mln
Brief: Erytech Pharma SA- Expands Patent Portfolio For Treatment Of Rare Metabolic Diseases
Brief: Erytech: Positive Results Of Two Clinical Trials Of Eryaspase In Pancreatic Cancer
Brief: Erytech Announces Results Of Expanded Access Program In ALL
Brief: ERYTECH Announces $7.85 Mln Registered Direct Offering With Armistice
Erytech Pharma rises on new U.S. patent
Brief: Erytech Pharma SA Secures U.S. Patent Directed To Sequential Use Of Methioninase & Asparaginase Against Solid Tumors